Research Topics
| Martin GutierrezSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-RWyndham H Wilson
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Semin Oncol 29:41-7. 2002..These results suggest that rituximab may modulate the sensitivity of B-cell lymphomas to chemotherapy...- Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacyWyndham H Wilson
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Blood 99:2685-93. 2002..Dose-adjusted EPOCH may produce more cell kill than CHOP-based regimens. Dynamic dose adjustment may overcome inadequate drug concentrations, particularly in younger patients, and compensate for increased drug clearance over time... - Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biologyRichard F Little
Center for Cancer Research (CCR, National Cancer Institute (NCI, National Institutes of Health, Bethesda, MD 20892, USA
Blood 101:4653-9. 2003..These results suggest that tumor pathogenesis is responsible for the improved outcome of ARLs in the era of HAART... - Patient perspectives on phase 0 clinical trialsMartin Gutierrez
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 14:3689-91. 2008 - Designing phase 0 cancer clinical trialsAnthony J Murgo
Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 2440, USA
Clin Cancer Res 14:3675-82. 2008.... - Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersWyndham H Wilson
Metabolism Branch, National Cancer Institute, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Clin Oncol 26:2717-24. 2008.... - Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomasSherry X Yang
Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
Cancer Biol Ther 8:2004-9. 2009..We aimed to determine whether the PARP inhibitor ABT-888 hits its therapeutic target in tumors by immunohistochemistry during a Phase 0 trial conducted at the National Cancer Institute... - Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignanciesShivaani Kummar
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 13:5411-7. 2007..The aims of this phase I trial were to determine the dose-limiting toxicities and maximum tolerated dose of oral MS-275 in humans administered with food on a once weekly schedule and to study the pharmacokinetics of oral MS-275... - Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphomaJohn E Janik
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 104:3355-7. 2004..Serum sIL-2R levels were elevated in both patients with recurrent disease... - Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer TherapiesShivaani Kummar
Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
Eur J Cancer 45:741-6. 2009..Construction of a 'decision chart' was highly recommended to assist investigators and sponsors in determining whether an agent is suitable for evaluation in a Phase 0 trial... - Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylationTsoching Chen
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Anal Chem 80:6390-6. 2008..The data demonstrate a new approach to a sensitive assessment of global molecular modifications that is independent of antibodies, requires minimal cell processing, and is easily adapted to high-throughput screening... - Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapyNilofer S Azad
Medical Oncology Branch, Biostatistics and Data Management Section, Center for Cancer Research, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 15:1411-6. 2009..We retrospectively analyzed dermatologic toxicity in patients receiving combined antiangiogenic therapy involving sorafenib and bevacizumab... - Drug development in oncology: classical cytotoxics and molecularly targeted agentsShivaani Kummar
Medical Oncology Branch, Center for Cancer Research and Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
Br J Clin Pharmacol 62:15-26. 2006..Thus, there is an increasing interest in making the best possible use of biomarkers and pharmacogenomics in early phases of drug development... - Compressing drug development timelines in oncology using phase '0' trialsShivaani Kummar
Center for Cancer Research, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland, USA
Nat Rev Cancer 7:131-9. 2007..We expect that such trials will become a routine part of early-phase oncological drug development in the future... - Antiangiogenic therapy in nonsmall cell lung cancerMartin Gutierrez
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Curr Opin Oncol 20:176-82. 2008..This review summarizes recent findings on targeting mediators of angiogenesis, treatment options and molecular targets in development... - Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenibNancy M Chung
Arch Dermatol 142:1510-1. 2006 - Keratoacanthomas associated with sorafenib therapyHeidi H Kong
J Am Acad Dermatol 56:171-2. 2007 - Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders
Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, SAIC Frederick Inc, NCI Frederick, Frederick, Maryland 21702, USA
Mol Interv 7:325-34. 2007....